Program
Beclomethasone
Also written as “Beclomethasone dipropionate”, “Beclometasone/Formoterol/Glycopyrrolate” and “beclomethasone”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, Perennial · Graft vs Host Disease, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chiesi Farmaceutici | 220 open or running | phase 4since Oct 28, 2020 | Sep 29, 2006 | none ahead |
| Teva Pharmaceutical Industries | 140 open or running | phase 4since Oct 28, 2003 | Oct 28, 2003 | none ahead |
| Soligenix | 30 open or running | phase 3since Jun 19, 2009 | Jun 19, 2009 | none ahead |
| Adamis Pharmaceuticals | 20 open or running | phase 3since Feb 6, 2019 | Feb 6, 2019 | none ahead |
| Enteron Pharmaceuticals | 10 open or running | phase 3since Oct 4, 2005 | Oct 4, 2005 | none ahead |
| Lunan Pharmaceutical Group | 11 open or running | phase 3since Jul 21, 2026 | Jul 21, 2026 | Jun 2028phase 3 · NCT07768891 |
| SOFAR | 10 open or running | phase 1since Apr 26, 2021 | Apr 26, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 27 studies since Oct 28, 2003.
- Aug 16, 2013Phase 2 study in Chronic Gastrointestinal Graft vs Host DiseaseSoligenix · NCT01925950 · 2 enrolled · United States
- Jan 7, 20143 phase 3 studies in AsthmaTeva Pharmaceutical Industries · NCT02031640, NCT02040779, NCT02040766
- Jan 9, 2014Phase 1 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT02040597 · 42 enrolled · Poland
- Apr 11, 2014Phase 1 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT02119234 · 36 enrolled · Poland
- May 21, 2014Phase 2 study in AsthmaChiesi Farmaceutici · NCT02148120 · 60 enrolled · United Kingdom
- Nov 15, 2016Phase 1 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT02975843 · 28 enrolled
- Aug 23, 2017Phase 3 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT03268226 · 20 enrolled · Belgium, Hungary
- Feb 6, 2019Adamis Pharmaceuticals's first studies: 2 phase 3 studies in AsthmaNew to Adamis PharmaceuticalsAdamis Pharmaceuticals · NCT03834012, NCT03835871
- Oct 28, 2020Phase 4 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT04671355
- Apr 26, 2021SOFAR's first study: phase 1 study in Healthy Adult Male VolunteersNew to SOFARSOFAR · NCT04873063 · 28 enrolled · Italy
- Apr 27, 2021Phase 3 study in AsthmaChiesi Farmaceutici · NCT04886999 · 78 enrolled · Italy
- May 3, 2021Phase 3 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT04876677 · 25 enrolled · Belgium, Hungary
- Mar 4, 2022Phase 3 study in AsthmaChiesi Farmaceutici · NCT05292586 · 1,377 enrolled · United States
- Jul 21, 2026Lunan Pharmaceutical Group's first study: phase 3 study in AsthmaNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT07768891 · 416 planned · China
Ahead
- Jun 2028Primary completion: phase 3 study in AsthmaLunan Pharmaceutical Group · NCT07768891
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
Studies
All 44 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07768891Asthma · China | 3 | Recruiting | Lunan Pharmaceutical Group | Jun 2028 | 416 |
| NCT05292586Asthma · United States | 3 | Completed | Chiesi Farmaceutici | Jun 24, 2024 | 1,377 |
| NCT04876677Pulmonary Disease, Chronic Obstructive · Belgium, Hungary | 3 | Completed | Chiesi Farmaceutici | Jan 3, 2022 | 25 |
| NCT04886999Asthma · Italy | 3 | Completed | Chiesi Farmaceutici | Feb 1, 2023 | 78 |
| NCT04873063Healthy Adult Male Volunteers · Italy | 1 | Completed | SOFAR | Apr 28, 2022 | 28 |
| NCT04671355Pulmonary Disease, Chronic Obstructive | 4 | Withdrawn | Chiesi Farmaceutici | Dec 22, 2021 | 0 |
| NCT03835871Asthma | 3 | Withdrawn | Adamis Pharmaceuticals | Dec 2019 | 0 |
| NCT03834012Asthma | 3 | Withdrawn | Adamis Pharmaceuticals | Nov 2019 | 0 |
| NCT03268226Pulmonary Disease, Chronic Obstructive · Belgium, Hungary | 3 | Completed | Chiesi Farmaceutici | Jan 30, 2019 | 20 |
| NCT02975843Pulmonary Disease, Chronic Obstructive | 1 | Completed | Chiesi Farmaceutici | Mar 21, 2017 | 28 |
| NCT02148120Asthma · United Kingdom | 2 | Completed | Chiesi Farmaceutici | Oct 2014 | 60 |
| NCT02119234Pulmonary Disease, Chronic Obstructive · Poland | 1 | Completed | Chiesi Farmaceutici | Feb 2015 | 36 |
| NCT02040779Asthma · United States | 3 | Completed | Teva Pharmaceutical Industries | Dec 24, 2014 | 273 |
| NCT02040766Asthma · United States, Croatia, Mexico and more | 3 | Completed | Teva Pharmaceutical Industries | Feb 2016 | 628 |
| NCT02040597Pulmonary Disease, Chronic Obstructive · Poland | 1 | Completed | Chiesi Farmaceutici | Apr 2015 | 42 |
| NCT02031640Asthma · United States, Germany, Hungary and more | 3 | Completed | Teva Pharmaceutical Industries | Nov 2014 | 1,113 |
| NCT01925950Chronic Gastrointestinal Graft vs Host Disease · United States | 2 | Terminated | Soligenix | May 2015 | 2 |
| NCT01917331Pulmonary Disease, Chronic Obstructive · Hungary | 3 | Completed | Chiesi Farmaceutici | Jan 14, 2016 | 1,368 |
| NCT01783548Rhinitis, Allergic · United States | 3 | Completed | Teva Pharmaceutical Industries | Oct 2013 | 547 |
| NCT01803087Asthma · Poland | 2 | Completed | Chiesi Farmaceutici | Oct 2012 | 60 |
| NCT01658891Asthma in Children · Denmark | 3 | Withdrawn | Chiesi Farmaceutici | Nov 2015 | 0 |
| NCT01691677Acute Rhinosinusitis · Italy | 3 | Completed | Chiesi Farmaceutici | Jan 2014 | 166 |
| NCT01584492Asthma · Poland, Ukraine | 2 | Completed | Chiesi Farmaceutici | Feb 2013 | 59 |
| NCT01475032Asthma · Bulgaria, France, Germany and more | 3 | Completed | Chiesi Farmaceutici | Sep 2012 | 638 |
| NCT01307319Rhinitis, Allergic, Seasonal · United States | 3 | Completed | Teva Pharmaceutical Industries | Jul 2011 | 715 |
| NCT01134705Rhinitis, Allergic, Perennial · United States | 3 | Completed | Teva Pharmaceutical Industries | Oct 2010 | 474 |
| NCT01133626Rhinitis, Allergic, Perennial · United States | 3 | Completed | Teva Pharmaceutical Industries | Sep 2010 | 107 |
| NCT01073384Enteritis · United States | 2 | Completed | Soligenix | Jan 2012 | 16 |
| NCT01024608Rhinitis, Allergic, Seasonal · United States | 3 | Completed | Teva Pharmaceutical Industries | Feb 28, 2010 | 340 |
| NCT00988247Rhinitis, Allergic, Perennial · United States | 3 | Completed | Teva Pharmaceutical Industries | Feb 28, 2011 | 529 |
| NCT00926575Acute Gastrointestinal Graft vs Host Disease · United States | 3 | Terminated | Soligenix | Dec 2011 | 140 |
| NCT00861926Asthma · Bulgaria, Croatia, Czechia and more | 3 | Completed | Chiesi Farmaceutici | Dec 7, 2010 | 1,714 |
| NCT00854360Rhinitis, Allergic, Seasonal · United States | 2 | Completed | Teva Pharmaceutical Industries | May 2009 | 487 |
| NCT00497523Asthma · Poland, Ukraine | 3 | Completed | Chiesi Farmaceutici | 283 | |
| NCT00497237Asthma · Bulgaria, Italy, Ukraine | 3 | Completed | Chiesi Farmaceutici | Mar 2010 | 382 |
| NCT00476268Asthma | 3 | Completed | Chiesi Farmaceutici | Jan 2005 | 824 |
| NCT00413387Asthma · Austria, Poland, Ukraine | 3 | Completed | Chiesi Farmaceutici | Aug 2005 | 219 |
| NCT00394368Asthma · Poland, Ukraine | 3 | Completed | Chiesi Farmaceutici | 180 | |
| NCT00382889Asthma · Austria, Italy, Poland and more | 3 | Completed | Chiesi Farmaceutici | 480 | |
| NCT00250341Asthma · United States | 4 | Completed | Teva Pharmaceutical Industries | Sep 30, 2007 | 34 |
| NCT00233896Graft vs Host Disease · United States | 3 | Completed | Enteron Pharmaceuticals | 130 | |
| NCT00109668Asthma · United States, Puerto Rico | 3 | Completed | Teva Pharmaceutical Industries | Sep 30, 2006 | 415 |
| NCT00094016Asthma · United States, Puerto Rico | 3 | Completed | Teva Pharmaceutical Industries | Jun 30, 2006 | 440 |
| NCT00071552Asthma · United States | 4 | Terminated | Teva Pharmaceutical Industries | Jul 31, 2006 | 49 |
How it is read
Names in the registry
- “Beclomethasone dipropionate”, 6 entries
- “Beclometasone/Formoterol/Glycopyrrolate”, 2 entries
- “beclomethasone”, 2 entries
- “beclomethasone dipropionate plus formoterol fumarate combination”, 2 entries
- “Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium”, 2 entries
Conditions, from the studies’ own filings
- Asthma, 25 studies
- Pulmonary Disease, Chronic Obstructive, 7 studies
- Rhinitis, Allergic, Seasonal, 3 studies
- Rhinitis, Allergic, Perennial, 3 studies
- Graft vs Host Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.